Benzinga | Jul 21, 2021 09:41AM EDT

Codex DNA Shares Move Higher On Licensing, Supply Deal With TriLink For mRNA Capping Tech

* Codex DNA Inc (NASDAQ:DNAY) has announced a licensing and supply agreement with TriLink Biotechnologies, part of Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) for CleanCap technology.

* Codex DNA will integrate the mRNA capping technology into its suite of automated mRNA synthesis kits for the BioXp system and within the company's BioFoundry Services offering.

* Together, the technologies are expected to increase productivity and yields for mRNA synthesis workflows.

* Customers will now have the option to generate up to 16 biologically active mRNA constructs at a yield of at least 10 micrograms each from fully de novo synthesized and error-corrected genes in a single automated run.

* Price Action: DNAY shares are up 10.4% at $17.50, while MRVI shares are down 2.37% at $39.38 during the market session on the last check Wednesday.